Ocular dyskinesias in patients with Parkinson's disease treated with levodopa

Shimizu, Natsue; Cohen, Bernard; Bala, Stanley P.; Mendoza, Marina R.; Yahr, Melvin D.

doi:10.1002/ana.410010211

Cited by 22 publications

(26 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Confirming previous observations [2–4], we conclude that the AIEMs described here represent a particular form of LID affecting conjugate eye movements, hence can be referred to as ‘ocular dyskinesia’. They seem to be more frequent than previously reported in the literature.…”

Section: Discussionsupporting

confidence: 91%

Levodopa‐induced ocular dyskinesia in Parkinson's disease

Grötzsch

Sztajzel

Burkhard

2007

Euro J of Neurology

View full text Add to dashboard Cite

Levodopa (LD)-induced dyskinesia (LID), one of the most common motor complications in advanced Parkinson's disease (PD), involve mostly the limbs, trunk and head, but unusual locations have been reported including respiratory muscles, the face and the eyes. The aim of this study was to further investigate the frequency and characteristics of LD-related abnormal involuntary eye movements (AIEMs) in PD. Thirty-two patients with advanced PD and various motor complications were evaluated and videotaped in an ON and OFF state. We found AIEMs in five patients (16%) which were present exclusively during the ON state and which completely disappeared when OFF. They consisted of repeated, stereotyped upward and/or sideways gaze deviation movements, sometimes phasic, brief and jerky, sometimes tonic and sustained for several seconds. The main direction of gaze deviation was toward the side more affected by parkinsonism. AIEMs typically paralleled limb and trunk LID and were modulated by the same facilitation and inhibitory maneuvers. We concluded that AIEMs are not uncommon in advanced PD and represent a particular topography of LID, hence the term 'ocular dyskinesia' to designate these AIEMs that seem to have a specific pattern in PD as compared with other forms of parkinsonism.

show abstract

Section: Discussionsupporting

confidence: 91%

Levodopa‐induced ocular dyskinesia in Parkinson's disease

Grötzsch

Sztajzel

Burkhard

2007

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…Involuntary eye movements or “ocular dyskinesia” can occur in PD, usually accompanying dyskinesia in other body parts . The eye movements are either a slow and smooth reversal from one direction to another in a “to‐and‐fro” pattern, or more commonly an upward gaze deviation as seen in oculogyric crisis or dystonic reactions .…”

Section: Clinical Features Of Levodopa‐induced Complicationsmentioning

confidence: 99%

Clinical spectrum of levodopa‐induced complications

2014

View full text Add to dashboard Cite

The first years of Parkinson disease (PD) treatment are marked by good and sustained responses to dopaminergic therapy. With disease progression and longer exposure to levodopa (l-dopa), patients develop a range of l-dopa-induced complications that include motor and non-motor symptoms. Motor complications include motor fluctuations, characterized by periods of reduced benefit from the medication, and l-dopa-induced dyskinesia, characterized by emergence of hyperkinetic involuntary movements. Dyskinesia can occur at peak effect of l-dopa, at the beginning and end of dose, or between doses. These motor complications are often associated with fluctuations in non-motor symptoms, particularly fluctuations in neuropsychiatric, autonomic, and sensory symptoms. Recognizing such complications and understanding their relationship with the timing of l-dopa doses is essential for adequate diagnosis and management. Society.

show abstract

“…Disturbances in eyelid motor control, such as apraxia of eyelid opening or blepharospasm, may be seen in PD patients as a result of levodopa treatment. However, ocular dyskinesias are very uncommon 3, 4. We report on a patient with advanced PD and levodopa‐induced ocular dyskinesias occurring simultaneously with generalized peak‐dose chorea.…”

mentioning

confidence: 94%